This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Menu
Close
Support & Resources
Depo-Provera® (medroxyprogesterone acetate) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Depo-Provera is one long acting reversible contraception (LARC) to consider, whatever her lifestyle – on-the-go, between children, pregnancy scare, forgetful, change in relationship.
Available for over 30 years1
Administered every 12 weeks2*† – with a text reminder service (see below for details)
Your patients can set a reminder, helping them to remember to book an appointment for their next injection to be given on time.
Text DEPO and the date the injection was given to 83311 in this format DD.MM (e.g. DEPO 31.07).
Three weeks before the next injection is due a reminder text will be sent. After each injection, your patient will need to re-register for the service.
There are a few contraindications to be aware of with Depo-Provera:
Hypersensitivity to medroxyprogesterone acetate or to any of excipients listed in section 6.1 of the Summary of Product Characteristics
Depo-Provera should not be used during pregnancy, either for diagnosis or therapy.
To read the full special warnings and precautions for use for Depo-Provera and see a full list of adverse events, refer to the Summary of Product Characteristics. The benefits of contraceptive options and their risks must be evaluated individually for each woman. If any of the conditions/risk factors mentioned is present, the benefits of Depo-Provera use should be weighed against the possible risks for each individual woman and discussed with the woman before she decides to start using it. In the event of aggravation, exacerbation or first appearance of any of these conditions or risk factors, the woman should contact her physician. The physician should then decide on whether Depo-Provera use should be discontinued.
*Providing the first injection is given during the first five days of a normal menstrual cycle and subsequent injections are given no later than twelve weeks and five days after the previous injection.
†Depo-Provera does not protect against sexually transmitted infections (STIs).
‡Based on cost of one syringe, does not include cost of clinical appointment.
Please refer to Depo-Provera® (medroxyprogesterone acetate) Prescribing Information.
References
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024